Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Discover the complete record of transactions filed by King Rachel K., Director. Director active across 2 companies, notably NOVAVAX INC. In total, 11 filings have been logged. Breakdown: 1 buy · 1 sell. Total volume traded: €116k. History available since 19 May 2021. The latest transaction was disclosed on 12 June 2025 (Levée d'options). Regulator: SEC (Form 4). The full history is accessible without signup.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
11 of 11 declarations
Rachel K. King is a Board Member at Novavax Inc. She plays a key role in the governance of the company, contributing to the definition of its strategy and guiding its research efforts. Her experience in the biopharmaceutical sector is valuable in guiding Novavax in its vaccine development initiatives.